Status:
TERMINATED
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Non-Small-Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCL...
Eligibility Criteria
Inclusion
- histologic or cytologic diagnosis of NSCLC Stage IIIB or IV
- no prior systemic chemotherapy for advanced Non-Small Cell Lung Cancer
- Prior radiotherapy must be completed at least 4 weeks before study enrollment.
Exclusion
- estimated life expectancy of 12 weeks
- a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
- documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 2 weeks before enrollment
- significant weight loss (that is, \> 10%) over the previous 6 weeks before study entry.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00383331
Start Date
February 1 2007
End Date
January 1 2008
Last Update
June 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Rochester, Minnesota, United States, 55905